{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:37:33Z","timestamp":1792183053014,"version":"4.4.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci. China Life Sci."],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s11427-025-3059-3","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T04:12:35Z","timestamp":1768882355000},"page":"1921-1928","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Liposomes in tumor treatment: a double-edged sword"],"prefix":"10.1007","volume":"69","author":[{"given":"Guo","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haotian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixia","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senlin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phei Er","family":"Saw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"3059_CR1","doi-asserted-by":"publisher","first-page":"80","DOI":"10.12703\/r\/10-80","volume":"10","author":"D Ain","year":"2021","unstructured":"Ain, D., Shaikh, T., Manimala, S., and Ghebrehiwet, B. (2021). The role of complement in the tumor microenvironment. Fac Rev 10, 80.","journal-title":"Fac Rev"},{"key":"3059_CR2","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","volume":"65","author":"TM Allen","year":"2013","unstructured":"Allen, T.M., and Cullis, P.R. (2013). Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliver Rev 65, 36\u201348.","journal-title":"Adv Drug Deliver Rev"},{"key":"3059_CR3","doi-asserted-by":"publisher","first-page":"101950","DOI":"10.1016\/j.smim.2025.101950","volume":"78","author":"MR Artero","year":"2025","unstructured":"Artero, M.R., Minery, A., Nedelcev, L., Radanova, M., and Roumenina, L.T. (2025). Complement and the hallmarks of cancer. Semin Immunol 78, 101950.","journal-title":"Semin Immunol"},{"key":"3059_CR4","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/S0022-2836(65)80093-6","volume":"13","author":"AD Bangham","year":"1965","unstructured":"Bangham, A.D., Standish, M.M., and Watkins, J.C. (1965). Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 13, 238\u2013252.","journal-title":"J Mol Biol"},{"key":"3059_CR5","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","volume":"160","author":"YC Barenholz","year":"2012","unstructured":"Barenholz, Y.C. (2012). Doxil\u00ae\u2014the first FDA-approved nano-drug: lessons learned. J Control Release 160, 117\u2013134.","journal-title":"J Control Release"},{"key":"3059_CR6","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1158\/1078-0432.CCR-14-1860","volume":"21","author":"GL Beatty","year":"2015","unstructured":"Beatty, G.L., and Gladney, W.L. (2015). Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res 21, 687\u2013692.","journal-title":"Clin Cancer Res"},{"key":"3059_CR7","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.cell.2015.01.004","volume":"160","author":"E Bonavita","year":"2015","unstructured":"Bonavita, E., Gentile, S., Rubino, M., Maina, V., Papait, R., Kunderfranco, P., Greco, C., Feruglio, F., Molgora, M., Laface, I., et al. (2015). PTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancer. Cell 160, 700\u2013714.","journal-title":"Cell"},{"key":"3059_CR8","doi-asserted-by":"publisher","first-page":"5945","DOI":"10.1182\/blood-2012-04-420760","volume":"119","author":"P Boross","year":"2012","unstructured":"Boross, P., and Leusen, J.H.W. (2012). Boosting antibody therapy with complement. Blood 119, 5945\u20135947.","journal-title":"Blood"},{"key":"3059_CR9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0005-2736(99)00013-9","volume":"1418","author":"AJ Bradley","year":"1999","unstructured":"Bradley, A.J., Brooks, D.E., Norris-Jones, R., and Devine, D.V. (1999). C1q binding to liposomes is surface charge dependent and is inhibited by peptides consisting of residues 14\u201326 of the human C1qA chain in a sequence independent manner. Biochim Biophys Acta 1418, 19\u201330.","journal-title":"Biochim Biophys Acta"},{"key":"3059_CR10","doi-asserted-by":"publisher","first-page":"6107","DOI":"10.2147\/IJN.S139687","volume":"12","author":"W Brand","year":"2017","unstructured":"Brand, W., Noorlander, C.W., Giannakou, C., De Jong, W.H., Kooi, M.W., Park, M.V., Vandebriel, R.J., Bosselaers, I.E., Scholl, J.H., and Geertsma, R.E. (2017). Nanomedicinal products: a survey on specific toxicity and side effects. Int J Nanomedicine 12, 6107\u20136129.","journal-title":"Int J Nanomedicine"},{"key":"3059_CR11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/pharmaceutics9020012","volume":"9","author":"U Bulbake","year":"2017","unstructured":"Bulbake, U., Doppalapudi, S., Kommineni, N., and Khan, W. (2017). Liposomal formulations in clinical use: an updated review. Pharmaceutics 9, 12.","journal-title":"Pharmaceutics"},{"key":"3059_CR12","doi-asserted-by":"publisher","first-page":"10346","DOI":"10.1038\/ncomms10346","volume":"7","author":"R Bulla","year":"2016","unstructured":"Bulla, R., Tripodo, C., Rami, D., Ling, G.S., Agostinis, C., Guarnotta, C., Zorzet, S., Durigutto, P., Botto, M., and Tedesco, F. (2016). C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation. Nat Commun 7, 10346.","journal-title":"Nat Commun"},{"key":"3059_CR13","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0002-9394(02)01475-7","volume":"134","author":"MT Cahill","year":"2002","unstructured":"Cahill, M.T., Smith, B.T., and Fekrat, S. (2002). Adverse reaction characterized by chest pain, shortness of breath, and syncope associated with verteporfin (visudyne). Am J Ophthalmol 134, 281\u2013282.","journal-title":"Am J Ophthalmol"},{"key":"3059_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11427-022-2340-4","volume":"67","author":"J Cai","year":"2024","unstructured":"Cai, J., Xu, X., and Saw, P.E. (2024). Nanomedicine targeting ferroptosis to overcome anticancer therapeutic resistance. Sci China Life Sci 67, 19\u201340.","journal-title":"Sci China Life Sci"},{"key":"3059_CR15","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.2174\/092986709788803312","volume":"16","author":"C Carvalho","year":"2009","unstructured":"Carvalho, C., Santos, R.X., Cardoso, S., Correia, S., Oliveira, P.J., Santos, M.S., and Moreira, P.I. (2009). Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem 16, 3267\u20133285.","journal-title":"Curr Med Chem"},{"key":"3059_CR16","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1093\/annonc\/mdg374","volume":"14","author":"A Chanan-Khan","year":"2003","unstructured":"Chanan-Khan, A., Szebeni, J., Savay, S., Liebes, L., Rafique, N.M., Alving, C.R., and Muggia, F.M. (2003). Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil\u00ae): possible role in hypersensitivity reactions. Ann Oncol 14, 1430\u20131437.","journal-title":"Ann Oncol"},{"key":"3059_CR17","doi-asserted-by":"publisher","first-page":"4234","DOI":"10.4049\/jimmunol.146.12.4234","volume":"146","author":"A Chonn","year":"1991","unstructured":"Chonn, A., Cullis, P.R., and Devine, D.V. (1991). The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. J Immunol 146, 4234\u20134241.","journal-title":"J Immunol"},{"key":"3059_CR18","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1200\/JCO.2007.13.6606","volume":"26","author":"G Ferrandina","year":"2008","unstructured":"Ferrandina, G., Ludovisi, M., Lorusso, D., Pignata, S., Breda, E., Savarese, A., Del Medico, P., Scaltriti, L., Katsaros, D., Priolo, D., et al. (2008). Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol 26, 890\u2013896.","journal-title":"J Clin Oncol"},{"key":"3059_CR19","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.drup.2016.10.003","volume":"29","author":"AA Gabizon","year":"2016","unstructured":"Gabizon, A.A., Patil, Y., and La-Beck, N.M. (2016). New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy. Drug Resist Updat 29, 90\u2013106.","journal-title":"Drug Resist Updat"},{"key":"3059_CR20","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1634\/theoncologist.2013-0126","volume":"18","author":"JM Gibson","year":"2013","unstructured":"Gibson, J.M., Alzghari, S., Ahn, C., Trantham, H., and La-Beck, N.M. (2013). The role of pegylated liposomal doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trials. Oncologist 18, 1022\u20131031.","journal-title":"Oncologist"},{"key":"3059_CR21","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S0076-6879(76)44019-3","volume":"44","author":"G Gregoriadis","year":"1976","unstructured":"Gregoriadis, G. (1976). Enzyme entrapment in liposomes. Methods Enzymol 44, 218\u2013227.","journal-title":"Methods Enzymol"},{"key":"3059_CR22","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/j.1432-1033.1972.tb19710.x","volume":"24","author":"G Gregoriadis","year":"1972","unstructured":"Gregoriadis, G., and Ryman, B.E. (1972a). Fate of protein-containing liposomes injected into rats. Eur J Biochem 24, 485\u2013491.","journal-title":"Eur J Biochem"},{"key":"3059_CR23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1042\/bj1290123","volume":"129","author":"G Gregoriadis","year":"1972","unstructured":"Gregoriadis, G., and Ryman, B.E. (1972b). Lysosomal localization of \u03b2-fructofurano-sidase-containing liposomes injected into rats. Some implications in the treatment of genetic disorders. Biochem J 129, 123\u2013133.","journal-title":"Biochem J"},{"key":"3059_CR24","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1126\/science.7423203","volume":"210","author":"TD Heath","year":"1980","unstructured":"Heath, T.D., Fraley, R.T., and Papahdjopoulos, D. (1980). Antibody targeting of liposomes: cell specificity obtained by conjugation of F(ab\u2032)2 to vesicle surface. Science 210, 539\u2013541.","journal-title":"Science"},{"key":"3059_CR25","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.jconrel.2007.05.015","volume":"122","author":"T Ishida","year":"2007","unstructured":"Ishida, T., Wang, X.Y., Shimizu, T., Nawata, K., and Kiwada, H. (2007). PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. J Control Release 122, 349\u2013355.","journal-title":"J Control Release"},{"key":"3059_CR26","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nature05172","volume":"444","author":"BJC Janssen","year":"2006","unstructured":"Janssen, B.J.C., Christodoulidou, A., McCarthy, A., Lambris, J.D., and Gros, P. (2006). Structure of C3b reveals conformational changes that underlie complement activity. Nature 444, 213\u2013216.","journal-title":"Nature"},{"key":"3059_CR27","doi-asserted-by":"publisher","first-page":"3688","DOI":"10.1016\/j.biomaterials.2013.12.085","volume":"35","author":"Y Klapper","year":"2014","unstructured":"Klapper, Y., Hamad, O.A., Teramura, Y., Leneweit, G., Nienhaus, G.U., Ricklin, D., Lambris, J.D., Ekdahl, K.N., and Nilsson, B. (2014). Mediation of a non-proteolytic activation of complement component C3 by phospholipid vesicles. Biomaterials 35, 3688\u20133696.","journal-title":"Biomaterials"},{"key":"3059_CR28","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/0014-5793(90)81016-H","volume":"268","author":"AL Klibanov","year":"1990","unstructured":"Klibanov, A.L., Maruyama, K., Torchilin, V.P., and Huang, L. (1990). Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett 268, 235\u2013237.","journal-title":"FEBS Lett"},{"key":"3059_CR29","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.smim.2018.02.003","volume":"37","author":"M Kolev","year":"2018","unstructured":"Kolev, M., and Markiewski, M.M. (2018). Targeting complement-mediated immunoregulation for cancer immunotherapy. Semin Immunol 37, 85\u201397.","journal-title":"Semin Immunol"},{"key":"3059_CR30","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3389\/fphar.2019.00220","volume":"10","author":"NM La-Beck","year":"2019","unstructured":"La-Beck, N.M., Liu, X., and Wood, L.M. (2019). Harnessing liposome interactions with the immune system for the next breakthrough in cancer drug delivery. Front Pharmacol 10, 220.","journal-title":"Front Pharmacol"},{"key":"3059_CR31","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/288602a0","volume":"288","author":"LD Leserman","year":"1980","unstructured":"Leserman, L.D., Barbet, J., Kourilsky, F., and Weinstein, J.N. (1980). Targeting to cells of fluorescent liposomes covalently coupled with monoclonal antibody or protein A. Nature 288, 602\u2013604.","journal-title":"Nature"},{"key":"3059_CR32","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1080\/17435889.2024.2402677","volume":"19","author":"Y Li","year":"2024","unstructured":"Li, Y., He, J., Liu, J., Um, W., and Ding, J. (2024). Challenges and opportunities of poly (amino acid) nanomedicines in cancer therapy. Nanomedicine 19, 2495\u20132504.","journal-title":"Nanomedicine"},{"key":"3059_CR33","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1007\/s11427-022-2329-7","volume":"66","author":"S Liu","year":"2023","unstructured":"Liu, S., Zhang, F., Liang, Y., Wu, G., Liu, R., Li, X., Saw, P.E., and Yang, Z. (2023). Nanoparticle (NP)-mediated APOC1 silencing to inhibit MAPK\/ERK and NF-\u03baB pathway and suppress breast cancer growth and metastasis. Sci China Life Sci 66, 2451\u20132465.","journal-title":"Sci China Life Sci"},{"key":"3059_CR34","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1093\/annonc\/mdl477","volume":"18","author":"D Lorusso","year":"2007","unstructured":"Lorusso, D., Di Stefano, A., Carone, V., Fagotti, A., Pisconti, S., and Scambia, G. (2007). Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia (\u2018hand-foot\u2019 syndrome). Ann Oncol 18, 1159\u20131164.","journal-title":"Ann Oncol"},{"key":"3059_CR35","doi-asserted-by":"publisher","first-page":"S210","DOI":"10.21037\/jtd.2019.02.21","volume":"11","author":"M Magalh\u00e3es Filho","year":"2019","unstructured":"Magalh\u00e3es Filho, M., Aguiar Junior, P.N., Adashek, J.J., and De Mello, R.A. (2019). How complement activation via a C3a receptor pathway alters CD4+ T lymphocytes and mediates lung cancer progression?\u2014future perspectives. J Thorac Dis 11, S210\u2013S211.","journal-title":"J Thorac Dis"},{"key":"3059_CR36","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.imbio.2015.11.008","volume":"222","author":"S Mamidi","year":"2017","unstructured":"Mamidi, S., H\u00f6ne, S., and Kirschfink, M. (2017). The complement system in cancer: ambivalence between tumour destruction and promotion. Immunobiology 222, 45\u201354.","journal-title":"Immunobiology"},{"key":"3059_CR37","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1038\/ni.1655","volume":"9","author":"MM Markiewski","year":"2008","unstructured":"Markiewski, M.M., DeAngelis, R.A., Benencia, F., Ricklin-Lichtsteiner, S.K., Koutoulaki, A., Gerard, C., Coukos, G., and Lambris, J.D. (2008). Modulation of the antitumor immune response by complement. Nat Immunol 9, 1225\u20131235.","journal-title":"Nat Immunol"},{"key":"3059_CR38","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.it.2009.04.002","volume":"30","author":"MM Markiewski","year":"2009","unstructured":"Markiewski, M.M., and Lambris, J.D. (2009). Is complement good or bad for cancer patients? A new perspective on an old dilemma. Trends Immunol 30, 286\u2013292.","journal-title":"Trends Immunol"},{"key":"3059_CR39","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41577-023-00926-1","volume":"24","author":"DC Mastellos","year":"2024","unstructured":"Mastellos, D.C., Hajishengallis, G., and Lambris, J.D. (2024). A guide to complement biology, pathology and therapeutic opportunity. Nat Rev Immunol 24, 118\u2013141.","journal-title":"Nat Rev Immunol"},{"key":"3059_CR40","doi-asserted-by":"publisher","first-page":"101205","DOI":"10.1016\/j.mam.2023.101205","volume":"93","author":"R Mattioli","year":"2023","unstructured":"Mattioli, R., Ilari, A., Colotti, B., Mosca, L., Fazi, F., and Colotti, G. (2023). Doxorubicin and other anthracyclines in cancers: activity, chemoresistance and its overcoming. Mol Aspects Med 93, 101205.","journal-title":"Mol Aspects Med"},{"key":"3059_CR41","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.ccell.2018.09.003","volume":"34","author":"TR Medler","year":"2018","unstructured":"Medler, T.R., Murugan, D., Horton, W., Kumar, S., Cotechini, T., Forsyth, A.M., Leyshock, P., Leitenberger, J.J., Kulesz-Martin, M., Margolin, A.A., et al. (2018). Complement C5a fosters squamous carcinogenesis and limits T cell response to chemotherapy. Cancer Cell 34, 561\u2013578.e6.","journal-title":"Cancer Cell"},{"key":"3059_CR42","doi-asserted-by":"crossref","unstructured":"Merle, N.S., Church, S.E., Fremeaux-Bacchi, V., and Roumenina, L.T. (2015). Complement system part I\u2014molecular mechanisms of activation and regulation. Front Immunol 6.","DOI":"10.3389\/fimmu.2015.00262"},{"key":"3059_CR43","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jconrel.2014.03.051","volume":"190","author":"SM Moghimi","year":"2014","unstructured":"Moghimi, S.M. (2014). Cancer nanomedicine and the complement system activation paradigm: anaphylaxis and tumour growth. J Control Release 190, 556\u2013562.","journal-title":"J Control Release"},{"key":"3059_CR44","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1080\/08982100802309552","volume":"18","author":"SM Moghimi","year":"2008","unstructured":"Moghimi, S.M., and Hamad, I. (2008). Liposome-mediated triggering of complement cascade. J Liposome Res 18, 195\u2013209.","journal-title":"J Liposome Res"},{"key":"3059_CR45","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1096\/fj.06-6186fje","volume":"20","author":"S Moein Moghimi","year":"2006","unstructured":"Moein Moghimi, S., Hamad, I., Andresen, T.L., J\u00f8rgensen, K., Szebeni, J., Moein Moghimi, S., Hamad, I., Andresen, T.L., J\u00f8rgensen, K., and Szebeni, J. (2006). Methylation of the phosphate oxygen moiety of phospholipid-methoxy (polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production. FASEB J 20, 2591\u20132593.","journal-title":"FASEB J"},{"key":"3059_CR46","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/S0163-7827(03)00033-X","volume":"42","author":"SM Moghimi","year":"2003","unstructured":"Moghimi, S.M., and Szebeni, J. (2003). Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res 42, 463\u2013478.","journal-title":"Prog Lipid Res"},{"key":"3059_CR47","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1080\/14686996.2019.1627174","volume":"20","author":"M Mohamed","year":"2019","unstructured":"Mohamed, M., Abu Lila, A.S., Shimizu, T., Alaaeldin, E., Hussein, A., Sarhan, H.A., Szebeni, J., and Ishida, T. (2019). PEGylated liposomes: immunological responses. Sci Tech Adv Mater 20, 710\u2013724.","journal-title":"Sci Tech Adv Mater"},{"key":"3059_CR48","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0049475514543655","volume":"44","author":"P Nath","year":"2014","unstructured":"Nath, P., Basher, A., Harada, M., Sarkar, S., Selim, S., Maude, R.J., Noiri, E., and Faiz, A. (2014). Immediate hypersensitivity reaction following liposomal amphotericin-B (AmBisome) infusion. Trop Doct 44, 241\u2013242.","journal-title":"Trop Doct"},{"key":"3059_CR49","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1593\/neo.121262","volume":"14","author":"S Nunez-Cruz","year":"2012","unstructured":"Nunez-Cruz, S., Gimotty, P.A., Guerra, M.W., Connolly, D.C., Wu, Y.Q., DeAngelis, R. A., Lambris, J.D., Coukos, G., and Scholler, N. (2012). Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization. Neoplasia 14, 994\u20131004.","journal-title":"Neoplasia"},{"key":"3059_CR50","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1093\/annonc\/mdh097","volume":"15","author":"MER O\u2019Brien","year":"2004","unstructured":"O\u2019Brien, M.E.R., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D.G., Tomczak, P., Ackland, S.P., et al. (2004). Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\u2122\/Doxil\u00ae) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer. Ann Oncol 15, 440\u2013449.","journal-title":"Ann Oncol"},{"key":"3059_CR51","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.semcancer.2012.01.011","volume":"22","author":"S Ostrand-Rosenberg","year":"2012","unstructured":"Ostrand-Rosenberg, S., Sinha, P., Beury, D.W., and Clements, V.K. (2012). Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin Cancer Biol 22, 275\u2013281.","journal-title":"Semin Cancer Biol"},{"key":"3059_CR52","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1016\/j.bbrc.2004.09.198","volume":"324","author":"M Otsuka","year":"2004","unstructured":"Otsuka, M., Tsuchiya, S., and Aramaki, Y. (2004). Involvement of ERK, a MAP kinase, in the production of TGF-\u03b2 by macrophages treated with liposomes composed of phosphatidylserine. Biochem Biophys Res Commun 324, 1400\u20131405.","journal-title":"Biochem Biophys Res Commun"},{"key":"3059_CR53","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.addr.2013.12.008","volume":"66","author":"B Ozpolat","year":"2014","unstructured":"Ozpolat, B., Sood, A.K., and Lopez-Berestein, G. (2014). Liposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliver Rev 66, 110\u2013116.","journal-title":"Adv Drug Deliver Rev"},{"key":"3059_CR54","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.4049\/jimmunol.0902214","volume":"184","author":"MB Pedersen","year":"2010","unstructured":"Pedersen, M.B., Zhou, X., Larsen, E.K.U., S\u00f8rensen, U.S., Kjems, J., Nygaard, J.V., Nyengaard, J.R., Meyer, R.L., Boesen, T., and Vorup-Jensen, T. (2010). Curvature of synthetic and natural surfaces is an important target feature in classical pathway complement activation. J Immunol 184, 1931\u20131945.","journal-title":"J Immunol"},{"key":"3059_CR55","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jconrel.2016.04.028","volume":"232","author":"GH Petersen","year":"2016","unstructured":"Petersen, G.H., Alzghari, S.K., Chee, W., Sankari, S.S., and La-Beck, N.M. (2016). Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin. J Control Release 232, 255\u2013264.","journal-title":"J Control Release"},{"key":"3059_CR56","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1074\/jbc.M110.180760","volume":"286","author":"CTN Pham","year":"2011","unstructured":"Pham, C.T.N., Mitchell, L.M., Huang, J.L., Lubniewski, C.M., Schall, O.F., Killgore, J.K., Pan, D., Wickline, S.A., Lanza, G.M., and Hourcade, D.E. (2011). Variable antibody-dependent activation of complement by functionalized phospholipid nanoparticle surfaces. J Biol Chem 286, 123\u2013130.","journal-title":"J Biol Chem"},{"key":"3059_CR57","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.smim.2013.04.001","volume":"25","author":"R Pio","year":"2013","unstructured":"Pio, R., Ajona, D., and Lambris, J.D. (2013). Complement inhibition in cancer therapy. Semin Immunol 25, 54\u201364.","journal-title":"Semin Immunol"},{"key":"3059_CR58","doi-asserted-by":"publisher","first-page":"774","DOI":"10.3389\/fimmu.2019.00774","volume":"10","author":"R Pio","year":"2019","unstructured":"Pio, R., Ajona, D., Ortiz-Espinosa, S., Mantovani, A., and Lambris, J.D. (2019). Complementing the cancer-immunity cycle. Front Immunol 10, 774.","journal-title":"Front Immunol"},{"key":"3059_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40242-024-4180-8","volume":"41","author":"C Qin","year":"2025","unstructured":"Qin, C., Yang, G., Wei, Q., Xin, H., Ding, J., and Chen, X. (2025). Multidimensional role of amino acid metabolism in immune regulation: from molecular mechanisms to therapeutic strategies. Chem Res Chin Univ 41, 1\u201314.","journal-title":"Chem Res Chin Univ"},{"key":"3059_CR60","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jconrel.2017.12.023","volume":"271","author":"R Rajan","year":"2018","unstructured":"Rajan, R., Sabnani, M.K., Mavinkurve, V., Shmeeda, H., Mansouri, H., Bonkoungou, S., Le, A.D., Wood, L.M., Gabizon, A.A., and La-Beck, N.M. (2018). Liposome-induced immunosuppression and tumor growth is mediated by macrophages and mitigated by liposome-encapsulated alendronate. J Control Release 271, 139\u2013148.","journal-title":"J Control Release"},{"key":"3059_CR61","doi-asserted-by":"publisher","first-page":"3218","DOI":"10.4049\/jimmunol.2000511","volume":"205","author":"B Reese","year":"2020","unstructured":"Reese, B., Silwal, A., Daugherity, E., Daugherity, M., Arabi, M., Daly, P., Paterson, Y., Woolford, L., Christie, A., Elias, R., et al. (2020). Complement as prognostic biomarker and potential therapeutic target in renal cell carcinoma. J Immunol 205, 3218\u20133229.","journal-title":"J Immunol"},{"key":"3059_CR62","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/nri.2017.97","volume":"18","author":"ES Reis","year":"2018","unstructured":"Reis, E.S., Mastellos, D.C., Ricklin, D., Mantovani, A., and Lambris, J.D. (2018). Complement in cancer: untangling an intricate relationship. Nat Rev Immunol 18, 5\u201318.","journal-title":"Nat Rev Immunol"},{"key":"3059_CR63","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/ni.1923","volume":"11","author":"D Ricklin","year":"2010","unstructured":"Ricklin, D., Hajishengallis, G., Yang, K., and Lambris, J.D. (2010). Complement: a key system for immune surveillance and homeostasis. Nat Immunol 11, 785\u2013797.","journal-title":"Nat Immunol"},{"key":"3059_CR64","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.nano.2014.08.010","volume":"11","author":"MK Sabnani","year":"2015","unstructured":"Sabnani, M.K., Rajan, R., Rowland, B., Mavinkurve, V., Wood, L.M., Gabizon, A.A., and La-Beck, N.M. (2015). Liposome promotion of tumor growth is associated with angiogenesis and inhibition of antitumor immune responses. Nanomedicine 11, 259\u2013262.","journal-title":"Nanomedicine"},{"key":"3059_CR65","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1007\/s10544-009-9336-2","volume":"11","author":"X Shan","year":"2009","unstructured":"Shan, X., Yuan, Y., Liu, C., Tao, X., Sheng, Y., and Xu, F. (2009). Influence of PEG chain on the complement activation suppression and longevity in vivo prolongation of the PCL biomedical nanoparticles. Biomed Microdevices 11, 1187\u20131194.","journal-title":"Biomed Microdevices"},{"key":"3059_CR66","doi-asserted-by":"publisher","first-page":"6083","DOI":"10.1158\/1078-0432.CCR-14-0493","volume":"20","author":"G Song","year":"2014","unstructured":"Song, G., Darr, D.B., Santos, C.M., Ross, M., Valdivia, A., Jordan, J.L., Midkiff, B.R., Cohen, S., Nikolaishvili-Feinberg, N., Miller, C.R., et al. (2014). Effects of Tumor microenvironment heterogeneity on nanoparticle disposition and efficacy in breast cancer tumor models. Clin Cancer Res 20, 6083\u20136095.","journal-title":"Clin Cancer Res"},{"key":"3059_CR67","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v18.i6.50","volume":"18","author":"J Szebeni","year":"2001","unstructured":"Szebeni, J. (2001). Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs, and radiocontrast agents. Crit Rev Ther Drug Carrier Syst 18, 567\u2013606.","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"3059_CR68","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.tox.2005.07.023","volume":"216","author":"J Szebeni","year":"2005","unstructured":"Szebeni, J. (2005). Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology 216, 106\u2013121.","journal-title":"Toxicology"},{"key":"3059_CR69","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.molimm.2014.06.038","volume":"61","author":"J Szebeni","year":"2014","unstructured":"Szebeni, J. (2014). Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals. Mol Immunol 61, 163\u2013173.","journal-title":"Mol Immunol"},{"key":"3059_CR70","doi-asserted-by":"publisher","first-page":"H1319","DOI":"10.1152\/ajpheart.2000.279.3.H1319","volume":"279","author":"J Szebeni","year":"2000","unstructured":"Szebeni, J., Baranyi, L., Savay, S., Bodo, M., Morse, D.S., Basta, M., Stahl, G.L., B\u00fcnger, R., and Alving, C.R. (2000). Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction. Am J Physiol Heart Circ Physiol 279, H1319\u2013H1328.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"3059_CR71","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.addr.2011.06.017","volume":"63","author":"J Szebeni","year":"2011","unstructured":"Szebeni, J., Muggia, F., Gabizon, A., and Barenholz, Y. (2011). Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. Adv Drug Deliver Rev 63, 1020\u20131030.","journal-title":"Adv Drug Deliver Rev"},{"key":"3059_CR72","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.bbrc.2015.06.177","volume":"468","author":"J Szebeni","year":"2015","unstructured":"Szebeni, J., and Storm, G. (2015). Complement activation as a bioequivalence issue relevant to the development of generic liposomes and other nanoparticulate drugs. Biochem Biophys Res Commun 468, 490\u2013497.","journal-title":"Biochem Biophys Res Commun"},{"key":"3059_CR73","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nrc3581","volume":"13","author":"JE Talmadge","year":"2013","unstructured":"Talmadge, J.E., and Gabrilovich, D.I. (2013). History of myeloid-derived suppressor cells. Nat Rev Cancer 13, 739\u2013752.","journal-title":"Nat Rev Cancer"},{"key":"3059_CR74","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.smim.2016.03.003","volume":"28","author":"RP Taylor","year":"2016","unstructured":"Taylor, R.P., and Lindorfer, M.A. (2016). Cytotoxic mechanisms of immunotherapy: harnessing complement in the action of anti-tumor monoclonal antibodies. Semin Immunol 28, 309\u2013316.","journal-title":"Semin Immunol"},{"key":"3059_CR75","doi-asserted-by":"publisher","first-page":"3454","DOI":"10.1158\/0008-5472.CAN-14-0157","volume":"74","author":"SK Vadrevu","year":"2014","unstructured":"Vadrevu, S.K., Chintala, N.K., Sharma, S.K., Sharma, P., Cleveland, C., Riediger, L., Manne, S., Fairlie, D.P., Gorczyca, W., Almanza, O., et al. (2014). Complement C5a receptor facilitates cancer metastasis by altering T-cell responses in the metastatic niche. Cancer Res 74, 3454\u20133465.","journal-title":"Cancer Res"},{"key":"3059_CR76","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1002\/jbm.a.30711","volume":"78A","author":"A Vonarbourg","year":"2006","unstructured":"Vonarbourg, A., Passirani, C., Saulnier, P., Simard, P., Leroux, J.C., and Benoit, J.P. (2006). Evaluation of pegylated lipid nanocapsules versus complement system activation and macrophage uptake. J Biomed Mater Res A 78A, 620\u2013628.","journal-title":"J Biomed Mater Res A"},{"key":"3059_CR77","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.jconrel.2007.02.010","volume":"119","author":"XY Wang","year":"2007","unstructured":"Wang, X.Y., Ishida, T., and Kiwada, H. (2007). Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. J Control Release 119, 236\u2013244.","journal-title":"J Control Release"},{"key":"3059_CR78","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1158\/2159-8290.CD-15-1412","volume":"6","author":"Y Wang","year":"2016","unstructured":"Wang, Y., Sun, S.N., Liu, Q., Yu, Y.Y., Guo, J., Wang, K., Xing, B.C., Zheng, Q.F., Campa, M.J., Patz Jr, E.F., et al. (2016). Autocrine complement inhibits IL10-dependent T-cell\u2014mediated antitumor immunity to promote tumor progression. Cancer Discov 6, 1022\u20131035.","journal-title":"Cancer Discov"},{"key":"3059_CR79","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.3390\/ijms23031912","volume":"23","author":"BB Wu","year":"2022","unstructured":"Wu, B.B., Leung, K.T., and Poon, E.N.Y. (2022). Mitochondrial-targeted therapy for doxorubicin-induced cardiotoxicity. Int J Mol Sci 23, 1912.","journal-title":"Int J Mol Sci"},{"key":"3059_CR80","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/imr.13147","volume":"313","author":"A Zarantonello","year":"2023","unstructured":"Zarantonello, A., Revel, M., Grunenwald, A., and Roumenina, L.T. (2023). C3-dependent effector functions of complement. Immunol Rev 313, 120\u2013138.","journal-title":"Immunol Rev"},{"key":"3059_CR81","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1158\/2326-6066.CIR-18-0272","volume":"7","author":"H Zha","year":"2019","unstructured":"Zha, H., Wang, X., Zhu, Y., Chen, D., Han, X., Yang, F., Gao, J., Hu, C., Shu, C., Feng, Y., et al. (2019). Intracellular activation of complement C3 leads to PD-L1 antibody treatment resistance by modulating tumor-associated macrophages. Cancer Immunol Res 7, 193\u2013207.","journal-title":"Cancer Immunol Res"},{"key":"3059_CR82","doi-asserted-by":"publisher","first-page":"e2303261","DOI":"10.1002\/adma.202303261","volume":"35","author":"Y Zong","year":"2023","unstructured":"Zong, Y., Lin, Y., Wei, T., and Cheng, Q. (2023). Lipid nanoparticle (LNP) enables mRNA delivery for cancer therapy. Adv Mater 35, e2303261.","journal-title":"Adv Mater"},{"key":"3059_CR83","first-page":"20240385","volume":"46","author":"HY Zou","year":"2025","unstructured":"Zou, H.Y., Zhao, Z.T., Wang H.Z., Yang, J.Z., and Ding, J.X. (2025). Construction and assembly kinetics of amino acid-iron nano-assemblies. Chem J Chin Univ 46, 20240385.","journal-title":"Chem J Chin Univ"}],"container-title":["Science China Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11427-025-3059-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11427-025-3059-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11427-025-3059-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T09:03:00Z","timestamp":1780736580000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11427-025-3059-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":83,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["3059"],"URL":"https:\/\/doi.org\/10.1007\/s11427-025-3059-3","relation":{},"ISSN":["1674-7305","1869-1889"],"issn-type":[{"value":"1674-7305","type":"print"},{"value":"1869-1889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"assertion":[{"value":"23 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance and ethics"}}]}}